Xiong W - Search Results

1

Mitochondria Energy Metabolism Depression as Novel Adjuvant to Sensitize Radiotherapy and Inhibit Radiation Induced-Pulmonary Fibrosis.

Zhou Z, Jiang X, Yi L, Li C, Wang H, Xiong W, Li Z, Shen J. Zhou Z, et al. Among authors: xiong w. Adv Sci (Weinh). 2024 Jul;11(26):e2401394. doi: 10.1002/advs.202401394. Epub 2024 May 7. Adv Sci (Weinh). 2024. PMID: 38715382 Free PMC article.

2

RRM2 Regulates Sensitivity to Sunitinib and PD-1 Blockade in Renal Cancer by Stabilizing ANXA1 and Activating the AKT Pathway.

Xiong W, Zhang B, Yu H, Zhu L, Yi L, Jin X. Xiong W, et al. Adv Sci (Weinh). 2021 Sep;8(18):e2100881. doi: 10.1002/advs.202100881. Epub 2021 Jul 28. Adv Sci (Weinh). 2021. PMID: 34319001 Free PMC article.

3

Metabolic reprogramming mediated PD-L1 depression and hypoxia reversion to reactivate tumor therapy.

Zhou Z, Liu Y, Song W, Jiang X, Deng Z, Xiong W, Shen J. Zhou Z, et al. Among authors: xiong w. J Control Release. 2022 Dec;352:793-812. doi: 10.1016/j.jconrel.2022.11.004. Epub 2022 Nov 11. J Control Release. 2022. PMID: 36343761

4

Mitochondrial Disruption Nanosystem Simultaneously Depressed Programmed Death Ligand-1 and Transforming Growth Factor-β to Overcome Photodynamic Immunotherapy Resistance.

Jiang X, Yi L, Li C, Wang H, Xiong W, Li Y, Zhou Z, Shen J. Jiang X, et al. Among authors: xiong w. ACS Nano. 2024 Jan 30;18(4):3331-3348. doi: 10.1021/acsnano.3c10117. Epub 2024 Jan 16. ACS Nano. 2024. PMID: 38227812

5

A Hybrid Nanoadjuvant Simultaneously Depresses PD-L1/TGF-β1 and Activates cGAS-STING Pathway to Overcome Radio-Immunotherapy Resistance.

Yi L, Jiang X, Zhou Z, Xiong W, Xue F, Liu Y, Xu H, Fan B, Li Y, Shen J. Yi L, et al. Among authors: xiong w. Adv Mater. 2024 Apr;36(15):e2304328. doi: 10.1002/adma.202304328. Epub 2024 Jan 22. Adv Mater. 2024. PMID: 38229577

6

Mitochondria-Targeted Nanoadjuvants Induced Multi-Functional Immune-Microenvironment Remodeling to Sensitize Tumor Radio-Immunotherapy.

Zhou Z, Li C, Li C, Zhou L, Tan S, Hou W, Xie C, Wang L, Shen J, Xiong W. Zhou Z, et al. Among authors: xiong w. Adv Sci (Weinh). 2024 Jul;11(26):e2400297. doi: 10.1002/advs.202400297. Epub 2024 May 5. Adv Sci (Weinh). 2024. PMID: 38704675 Free PMC article.

7

Epigenetic-related gene-based prognostic model construction and validation in prostate adenocarcinoma.

Li Y, Li C, Wu L, Li J, Gan Y, Tan S, Zhou L, Xiong W, Zhou L, Li C, Liu J, Liu D, Wang Y, Fu Y, Yao K, Wang L. Li Y, et al. Among authors: xiong w. Heliyon. 2024 May 9;10(10):e30941. doi: 10.1016/j.heliyon.2024.e30941. eCollection 2024 May 30. Heliyon. 2024. PMID: 38779031 Free PMC article.

8

Endocrine cancer trends 1990-2021: global disparities and health inequalities.

Liu D, Zhou L, Li C, Li Y, Liu J, Zhou L, Tang J, Xiong W, Wang L. Liu D, et al. Among authors: xiong w. Endocr Relat Cancer. 2024 Oct 4;31(11):e230363. doi: 10.1530/ERC-23-0363. Print 2024 Nov 1. Endocr Relat Cancer. 2024. PMID: 39162682

9

Spatially Resolved Transcriptomics Technology Facilitates Cancer Research.

Wang Q, Zhi Y, Zi M, Mo Y, Wang Y, Liao Q, Zhang S, Gong Z, Wang F, Zeng Z, Guo C, Xiong W. Wang Q, et al. Among authors: xiong w. Adv Sci (Weinh). 2023 Oct;10(30):e2302558. doi: 10.1002/advs.202302558. Epub 2023 Aug 26. Adv Sci (Weinh). 2023. PMID: 37632718 Free PMC article. Review.

10

Targeting CBX3 with a Dual BET/PLK1 Inhibitor Enhances the Antitumor Efficacy of CDK4/6 Inhibitors in Prostate Cancer.

Liang H, Yang C, Zeng R, Song Y, Wang J, Xiong W, Yan B, Jin X. Liang H, et al. Among authors: xiong w. Adv Sci (Weinh). 2023 Dec;10(36):e2302368. doi: 10.1002/advs.202302368. Epub 2023 Nov 10. Adv Sci (Weinh). 2023. PMID: 37949681 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,882 results

Search Page

Filters